Login / Signup

Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis.

Paulo Caceres GuidoMariel PerezAlicia HalacMariela FerrariManuel IbarraNieves LicciardoneClaudio CastañosLuis P GravinaCristina JimenezFacundo Garcia BournissenPaula Schaiquevich
Published in: Pediatric pulmonology (2019)
The regimen of 30  mg-1  kg-1  day-1 every 24 hours more adequately fulfilled the therapeutic target for amikacin. Although all our patients had good clinical results and a good adverse-events profile, further studies are necessary to redefine the optimal treatment strategy.
Keyphrases
  • cystic fibrosis
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • pseudomonas aeruginosa
  • peritoneal dialysis
  • young adults
  • air pollution
  • smoking cessation